Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

CAH - Cardinal Health, Inc. Последние новости | Finranks

Home

/

CAH

C

Cardinal Health, Inc. (CAH)

NYQ – Цена в реальном времени. Валюта: USD

182.56

+0.06 (0.03%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Should Value Investors Buy Cardinal Health (CAH) Stock?

Should Value Investors Buy Cardinal Health (CAH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why Cardinal Health (CAH) is a Strong Value Stock

Here's Why Cardinal Health (CAH) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Down 14.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Cardinal (CAH)

Down 14.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Cardinal (CAH)

The heavy selling pressure might have exhausted for Cardinal (CAH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why Cardinal Health (CAH) is a Strong Growth Stock

Here's Why Cardinal Health (CAH) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Brokers Suggest Investing in Cardinal (CAH): Read This Before Placing a Bet

Brokers Suggest Investing in Cardinal (CAH): Read This Before Placing a Bet

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health Board of Directors Approves Quarterly Dividend

DUBLIN, Ohio, May 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026.

Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"

Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"

Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Видео

Cardinal Health CEO says Obamacare subsidies extension under review 'every single day'

Пресс-релизы

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health Board of Directors Approves Quarterly Dividend

DUBLIN, Ohio, May 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026.

Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook

Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook

Revenue increased 11% to $60.9 billion GAAP 1 operating earnings decreased 30% to $509 million; GAAP diluted EPS decreased 20% to $1.69 Non-GAAP operating earnings increased 18% to $956 million; non-GAAP diluted EPS increased 35% to $3.17 Cardinal Health raises and narrows fiscal year 2026 non-GAAP EPS guidance2 to $10.70 to $10.80 Cardinal Health reduces debt and completes additional $250 million share repurchase, bringing FY26 repurchase total to $1.0 billion DUBLIN, Ohio, April 30, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2026 revenues of $60.9 billion, an increase of 11% from the third quarter of fiscal year 2025. Third quarter GAAP operating earnings decreased 30% to $509 million and GAAP diluted earnings per share (EPS) decreased 20% to $1.69, reflecting a $184 million pre-tax goodwill impairment in the company's Navista & ION reporting unit primarily due to changes in the risk profile of the business plans resulting in an increase in the discount rate.

Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings

Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings

Research confirms advanced therapies are moving beyond inpatient hospitals, with providers increasingly supporting partnerships that bring life-changing treatments closer to patients' homes. DUBLIN, Ohio, April 14, 2026 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2026 Advanced Therapies Report: Perspectives on Community Expansion, offering new insights into how the expanding advanced therapy pipeline is reshaping sites of care.

Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies

Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies

DUBLIN, Ohio, April 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for Theranostics Advancement (CTA) in Indianapolis, Indiana. The addition of a high-capacity production line to its Drug Master File (DMF) will substantially increase Cardinal Health's supply of cGMP-compliant Ac-225 for use in investigational therapeutic drug products and future commercial manufacturing novel therapies.